NCT03078322 - AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions

Major Depressive Disorder

Interventions

DRUG

AV-101

Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)

DRUG

Placebo

Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Trial Locations (22)

10128

VistaGen Investigational Site, New York

14618

VistaGen Investigational Site, Rochester

19063

VistaGen Investigational Site, Media

20877

VistaGen Investigational Site, Gaithersburg

30331

VistaGen Investigational Site, Atlanta

30912

VistaGen Investigational Site, Augusta

32256

VistaGen Investigational Site, Jacksonville

33912

VistaGen Investigational Site, Fort Myers

45417

VistaGen Investigational Site, Dayton

60169

VistaGen Investigational Site, Hoffman Estates

63141

VistaGen Investigational Site, St Louis

70629

VistaGen Investigational Site, Lake Charles

73112

VistaGen Investigational Site, Oklahoma City

77030

VistaGen Investigational Site, Houston

77058

VistaGen Investigational Site, Houston

90024

VistaGen Investigational Site, Los Angeles

91950

VistaGen Investigational Site, National City

92103

VistaGen Investigational Site, San Diego

92591

VistaGen Investigational Site, Temecula

92845

VistaGen Investigational Site, Garden Grove

94607

VistaGen Investigational Site, Oakland

98007

VistaGen Investigational Site, Bellevue

All Listed Sponsors

lead

VistaGen Therapeutics, Inc.

INDUSTRY